Evangelista Sagnelli1, Mario Starace2, Carmine Minichini2, Mariantonietta Pisaturo2, Margherita Macera2, Caterina Sagnelli2, Nicola Coppola2. 1. Section of Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania Luigi Vanvitelli, Via: L. Armanni 5, 80131, Naples, Italy. evangelistasagnelli@libero.it. 2. Section of Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania Luigi Vanvitelli, Via: L. Armanni 5, 80131, Naples, Italy.
Abstract
BACKGROUND: Introduced in 2013-2014, the second- and third-wave directly acting antivirals (DAAs) have strongly enhanced the efficacy and tolerability of anti-HCV treatment, with a sustained virological response (SVR) in 90-95% of cases treated. The aim of this paper was to focus on the type and prevalence of viral strains with a reduced sensitivity to DAAs and on treatment choices for DAA-experienced patients. METHODS: The Medline was searched for "HCV infection", "HCV treatment", "Directly acting antivirals","HCV resistance". RESULTS: Most patients who did not achieve an SVR have been found to be infected with HCV mutant strains with a reduced susceptibility to these drugs. These mutants occur frequently in the NS5A region, with a moderate frequency in the NS3/4A regions and rarely in the NS5B region. Treatment-induced mutants resistant to NS5A DAAs persist for years after treatment discontinuation, whereas those resistant to the NS3 DAAs have a shorter duration. CONCLUSIONS: Patients who have failed HCV treatment with DAA agents have several re-treatment options, but re-treatment selection may be intricate and resistance testing is recommended to optimize this choice. It is, therefore, important to bear in mind that the correct determination of HCV genotype and subtype and the identification of RASs are essential elements for choosing the optimal re-treatment. It is supposed that it is useful to give readers some other suggestions regarding therapeutic reprocessing.
BACKGROUND: Introduced in 2013-2014, the second- and third-wave directly acting antivirals (DAAs) have strongly enhanced the efficacy and tolerability of anti-HCV treatment, with a sustained virological response (SVR) in 90-95% of cases treated. The aim of this paper was to focus on the type and prevalence of viral strains with a reduced sensitivity to DAAs and on treatment choices for DAA-experienced patients. METHODS: The Medline was searched for "HCV infection", "HCV treatment", "Directly acting antivirals","HCV resistance". RESULTS: Most patients who did not achieve an SVR have been found to be infected with HCV mutant strains with a reduced susceptibility to these drugs. These mutants occur frequently in the NS5A region, with a moderate frequency in the NS3/4A regions and rarely in the NS5B region. Treatment-induced mutants resistant to NS5A DAAs persist for years after treatment discontinuation, whereas those resistant to the NS3 DAAs have a shorter duration. CONCLUSIONS:Patients who have failed HCV treatment with DAA agents have several re-treatment options, but re-treatment selection may be intricate and resistance testing is recommended to optimize this choice. It is, therefore, important to bear in mind that the correct determination of HCV genotype and subtype and the identification of RASs are essential elements for choosing the optimal re-treatment. It is supposed that it is useful to give readers some other suggestions regarding therapeutic reprocessing.
Authors: Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns Journal: Lancet Infect Dis Date: 2016-02-18 Impact factor: 25.071
Authors: Weihua Wang; Yi Ren; Yang Lu; Yuan Xu; Seth D Crosby; Adrian M Di Bisceglie; Xiaofeng Fan Journal: Biotechniques Date: 2017-07-01 Impact factor: 1.993
Authors: Stefan Zeuzem; Graham R Foster; Stanley Wang; Armen Asatryan; Edward Gane; Jordan J Feld; Tarik Asselah; Marc Bourlière; Peter J Ruane; Heiner Wedemeyer; Stanislas Pol; Robert Flisiak; Fred Poordad; Wan-Long Chuang; Catherine A Stedman; Steven Flamm; Paul Kwo; Gregory J Dore; Gladys Sepulveda-Arzola; Stuart K Roberts; Ruth Soto-Malave; Kelly Kaita; Massimo Puoti; John Vierling; Edward Tam; Hugo E Vargas; Rafi Bruck; Francisco Fuster; Seung-Woon Paik; Franco Felizarta; Jens Kort; Bo Fu; Ran Liu; Teresa I Ng; Tami Pilot-Matias; Chih-Wei Lin; Roger Trinh; Federico J Mensa Journal: N Engl J Med Date: 2018-01-25 Impact factor: 91.245
Authors: Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen Journal: JAMA Date: 2012-12-26 Impact factor: 56.272
Authors: Eric J Lawitz; Hadas Dvory-Sobol; Brian P Doehle; Angela S Worth; John McNally; Diana M Brainard; John O Link; Michael D Miller; Hongmei Mo Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191
Authors: Marc Bourlière; Stuart C Gordon; Steven L Flamm; Curtis L Cooper; Alnoor Ramji; Myron Tong; Natarajan Ravendhran; John M Vierling; Tram T Tran; Stephen Pianko; Meena B Bansal; Victor de Lédinghen; Robert H Hyland; Luisa M Stamm; Hadas Dvory-Sobol; Evguenia Svarovskaia; Jie Zhang; K C Huang; G Mani Subramanian; Diana M Brainard; John G McHutchison; Elizabeth C Verna; Peter Buggisch; Charles S Landis; Ziad H Younes; Michael P Curry; Simone I Strasser; Eugene R Schiff; K Rajender Reddy; Michael P Manns; Kris V Kowdley; Stefan Zeuzem Journal: N Engl J Med Date: 2017-06-01 Impact factor: 91.245
Authors: Ana Paula de Torres Santos; Vanessa Cristina Martins Silva; Maria Cássia Mendes-Corrêa; Marcilio Figueiredo Lemos; Fernanda de Mello Malta; Rúbia Anita Ferraz Santana; Gregório Tadeu Fernando Dastoli; Vanessa Fusco Duarte de Castro; João Renato Rebello Pinho; Regina Célia Moreira Journal: Rev Inst Med Trop Sao Paulo Date: 2022-09-30 Impact factor: 2.169
Authors: Sarah K Inglis; Lewis Jz Beer; Christopher Byrne; Amy Malaguti; Emma Robinson; Christian Sharkey; Kirsty Gillings; Brian Stephens; John F Dillon Journal: BMJ Open Date: 2019-08-08 Impact factor: 2.692
Authors: Ana Paula de Torres Santos; Vanessa Cristina Martins Silva; Maria Cássia Mendes-Corrêa; Marcilio Figueiredo Lemos; Fernanda de Mello Malta; Rúbia Anita Ferraz Santana; Gregório Tadeu Fernando Dastoli; Vanessa Fusco Duarte de Castro; João Renato Rebello Pinho; Regina Célia Moreira Journal: Infect Drug Resist Date: 2021-02-24 Impact factor: 4.003
Authors: Matthew J Akiyama; Lindsey Riback; Jacqueline D Reeves; Yolanda S Lie; Linda Agyemang; Brianna L Norton; Julia H Arnsten; Alain H Litwin Journal: Open Forum Infect Dis Date: 2021-09-30 Impact factor: 3.835
Authors: Ashley N Matthew; Jacqueto Zephyr; Desaboini Nageswara Rao; Mina Henes; Wasih Kamran; Klajdi Kosovrasti; Adam K Hedger; Gordon J Lockbaum; Jennifer Timm; Akbar Ali; Nese Kurt Yilmaz; Celia A Schiffer Journal: mBio Date: 2020-03-31 Impact factor: 7.867